From the Canadian adverse reaction newsletter 24(4): Incretin-based drug products are new therapies indicated for the management of type 2 diabetes mellitus. Scientific studies have suggested that incretin-based therapies could possibly be associated with an increased risk of developing pancreatic cancer. In addition, cases of pancreatic cancer with the use of incretin-based therapies have been reported in Canada and internationally. A causal relationship between incretin-based therapies and the development of pancreatic cancer has not been established and investigations are ongoing. Health care professionals are encouraged to document and report to Health Canada any adverse reactions suspected of being associated with incretin-based therapies. Read more here.
No comments:
Post a Comment